Skip to main content
Caplight Logo









FibroNox

FibroNox

Private
Milton, GeorgiaHealthcare & Life Scienceshttps://fibronox.com/

Last Round

Grant

Jun 1, 2024

Total Funding Raised

$2.58M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

FibroNox is a biotechnology company that develops selective Nox4 inhibitors and Nrf2 activators to treat fibrotic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

fibrotic diseaseidiopathic pulmonary fibrosisIPFsmall-molecule therapeuticsNox4 inhibitorNrf2 activatordrug discoveryoxidative stressbiotech startuppre-clinical biotechDuchenne muscular dystrophyDMDdrug pipelineanti-fibrotictherapeutic developmentbiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

FibroNox Comparables

Compare FibroNox with similar companies based on industry and business-model similarity.

FibroNox comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Glucox Biotech AB
78%
Asahi Kasei
73%
Tvardi
73%

FibroNox Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 1, 2024
GrantMay 15, 2024
GrantSep 15, 2020
AcceleratorFeb 26, 2019

Key People

Founding team and executive leadership

Joseph Patti

President Chief Executive Officer, Executive Director

Executive Team

FibroNox Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 21, 2026

    Monthly visitors grew 484% MoM, reaching 1K.

  • Jun 1, 2024

    $2M grant from National Heart, Lung, and Blood Institute and NIH.

FibroNox Filings

Explore SEC and related filing metadata, where available.

FibroNox filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about FibroNox's valuation, stock price, and market status.

Is FibroNox a public or private company?

FibroNox is a private company.

What is the current stock price of FibroNox?

FibroNox is a private company with no public stock price. Caplight tracks FibroNox's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is FibroNox worth (valuation)?

Valuation information for FibroNox is not publicly available.

Can I buy FibroNox stock?

FibroNox shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was FibroNox's last funding round?

FibroNox's most recent funding round was Grant on June 1, 2024.

Who are the main investors in FibroNox?

Key investors in FibroNox include National Heart, Lung, and Blood Institute.

Will FibroNox IPO soon?

No public IPO plans have been announced for FibroNox.

How can I track FibroNox secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor FibroNox's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMilton, Georgia
Employee Range2
Year Founded2019
Last FundingJun 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?